Loading...
XLONCOG
Market cap17mUSD
Dec 24, Last price  
34.00GBP
1D
0.00%
1Q
-8.11%
Jan 2017
-50.72%
IPO
-59.28%
Name

Cambridge Cognition Holdings PLC

Chart & Performance

D1W1MN
XLON:COG chart
P/E
—
P/S
105.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.98%
Rev. gr., 5y
17.12%
Revenues
14m
+7.15%
4,828,3545,579,6575,683,6404,147,9995,802,0005,042,0006,876,0006,730,0006,134,0005,042,0006,741,00010,094,00012,613,00013,515,000
Net income
-4m
L+757.70%
719,610-160,725-1,576,024-2,861,000-173,000-782,000272,000-257,000-1,442,000-2,901,000-438,000450,000-409,000-3,508,000
CFO
-5m
L
550,161535,213-700,746-2,472,000-693,000-708,000473,000-624,000-644,000-2,315,0001,014,0003,934,0001,677,000-4,967,000
Earnings
Jun 27, 2025

Profile

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online trial recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I–IV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and NeuroVocalix for an automated administration and scoring of well-validated verbal cognitive assessments?on a secure platform. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.
URL
https://www.cambridgecognition.com/
IPO date
Apr 18, 2013
Employees
80
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,515
7.15%
12,613
24.96%
10,094
49.74%
Cost of revenue
15,686
13,549
9,547
Unusual Expense (Income)
NOPBT
(2,171)
(936)
547
NOPBT Margin
5.42%
Operating Taxes
51
(215)
(197)
Tax Rate
NOPAT
(2,222)
(721)
744
Net income
(3,508)
757.70%
(409)
-190.89%
450
-202.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
56
1,000
BB yield
-0.31%
0.00%
Debt
Debt current
584
18
18
Long-term debt
1,996
18
18
Deferred revenue
Other long-term liabilities
Net debt
(804)
(8,335)
(6,823)
Cash flow
Cash from operating activities
(4,967)
1,677
3,934
CAPEX
(33)
(189)
(56)
Cash from investing activities
(3,019)
(189)
(105)
Cash from financing activities
2,885
(132)
(86)
FCF
395
688
468
Balance
Cash
3,228
8,322
6,810
Long term investments
156
49
49
Excess cash
2,708
7,740
6,354
Stockholders' equity
(19,428)
(10,985)
(10,441)
Invested Capital
23,273
10,921
10,979
ROIC
6.74%
ROCE
1,462.50%
101.67%
EV
Common stock shares outstanding
34,597
31,170
31,519
Price
0.52
-54.82%
1.14
-9.88%
1.27
88.81%
Market cap
17,817
-49.86%
35,534
-10.88%
39,872
99.86%
EV
17,013
27,199
33,049
EBITDA
(1,506)
(842)
696
EV/EBITDA
47.48
Interest
168
16
11
Interest/NOPBT
2.01%